Histamine and the striatum  by Bolam, J. Paul & Ellender, Tommas J.
lable at ScienceDirect
Neuropharmacology 106 (2016) 74e84Contents lists avaiNeuropharmacology
journal homepage: www.elsevier .com/locate/neuropharmInvited reviewHistamine and the striatum
J. Paul Bolam, Tommas J. Ellender*
Department of Pharmacology, MRC Brain Network Dynamics Unit, Mansﬁeld Road, OX1 3TH Oxford, United Kingdoma r t i c l e i n f o
Article history:
Received 16 June 2015
Received in revised form
30 July 2015
Accepted 6 August 2015
Available online 11 August 2015
Keywords:
Histamine
Striatum
Basal ganglia
Tourette's syndrome
Parkinson's disease* Corresponding author.
E-mail address: tommas.ellender@pharm.ox.ac.uk
http://dx.doi.org/10.1016/j.neuropharm.2015.08.013
0028-3908/© 2015 The Authors. Published by Elseviea b s t r a c t
The neuromodulator histamine is released throughout the brain during periods of wakefulness. Com-
bined with an abundant expression of histamine receptors, this suggests potential widespread hista-
minergic control of neural circuit activity. However, the effect of histamine on many of these circuits is
unknown. In this review we will discuss recent evidence for histaminergic modulation of the basal
ganglia circuitry, and speciﬁcally its main input nucleus; the striatum. Furthermore, we will discuss
recent ﬁndings of histaminergic dysfunction in several basal ganglia disorders, including in Parkinson's
disease and most prominently, in Tourette's syndrome, which has led to a resurgence of interest in this
neuromodulator. Combined, these recent observations not only suggest a central role for histamine in
modulating basal ganglia activity and behaviour, but also as a possible target in treating basal ganglia
disorders.
This article is part of the Special Issue entitled ‘Histamine Receptors’.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Both the hypothalamus and basal ganglia are evolutionary
conserved brain structures essential for the survival of an organism.
The hypothalamus is a small structure at the base of the brain
important in controlling life-sustaining functions such as thermo-
regulation, metabolism and sleep and wakefulness, among others.
In addition, it is thought that the hypothalamus is able to control
the likelihood of more complex behavioural repertoires via its
widespread projections throughout the brain (Saper and Lowell,
2014). The posterior part of the hypothalamus includes the tuber-
omamillary nucleus (TMN) containing histaminergic neurons that
also project extensively and innervate nearly all regions of the brain
(Watanabe et al., 1983; Panula et al., 1984). Whereas the activity of
histaminergic neurons and the release of the neuromodulator
histamine have been shown to be important for maintaining
wakefulness and attention (White and Rumbold, 1988; Lin et al.,
1989; Parmentier et al., 2002; Anaclet et al., 2009) increasing evi-
dence suggests that histamine has wider functions in controlling
behaviour and neural circuit function.
The basal ganglia are a large collection of subcortical nuclei,
which play a central role in the control of motor behaviour, through(T.J. Ellender).
r Ltd. This is an open access articlthe selection and recruitment of appropriate motor programs
(Grillner et al., 2005), as well as cognitive function (Graybiel et al.,
1994; Grillner et al., 2005; Yin and Knowlton, 2006). The basal
ganglia receive a histaminergic projection (Takagi et al., 1986;
Airaksinen and Panula, 1988) and in particular the major input
nucleus of the basal ganglia, the striatum, expresses a high density
of histamine receptors (Hill and Young, 1980; Martinez-Mir et al.,
1990; Vizuete et al., 1997; Pillot et al., 2002) suggesting that his-
tamine can directly affect striatal function and basal ganglia output.
This reviewwill focus on the circuitry of the striatum, the role of
histamine in modulating striatal synaptic transmission and
behaviour and lastly the role of the histaminergic system in dis-
orders of the basal ganglia including in Parkinson's disease and in
Tourette's syndrome. We point to other excellent recent reviews
(Haas and Panula, 2003; Haas et al., 2008; Panula and Nuutinen,
2013) and reviews in this special issue of Neuropharmacology for
histaminergic modulation of sleep-wake states, molecular proper-
ties of histamine receptors and the expression proﬁles of speciﬁc
histamine receptor subtypes and other neurological disorders
linked to histamine dysfunction which we could not include for
brevity.
2. The basal ganglia and the striatum
The basal ganglia are an interconnected network of subcortical
nuclei (Fig. 1A), which play a critical role in the control of motore under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. (A) A simpliﬁed, schematic diagram of the basal ganglia (within the pale blue box) and their associated structures. Glutamatergic connections are in red, GABAergic con-
nections are in dark blue, dopaminergic connections are in yellow and histaminergic projections are in purple. The major excitatory afferents to the basal ganglia are from the cortex
and thalamus and are directed to both the striatum and the subthalamic nucleus (STN). The striatum inﬂuences the basal ganglia output nuclei substantia nigra pars reticulata (SNr)
and the internal segment of the globus pallidus (GPi) directly, or indirectly via connections with the network between the STN and external globus pallidus (GPe). The dopaminergic
substantia nigra pars compacta (SNc) inﬂuences the operation of the basal ganglia via connections with each nucleus. Similarly, the histaminergic tuberomamillary nucleus (TMN)
inﬂuences the basal ganglia as well as the input structures to the basal ganglia. The major targets of the basal ganglia output nuclei are the thalamus and the midbrain and brainstem
premotor regions, which inﬂuence movement via direct or indirect connections with motor nuclei. (B) Histaminergic neurons located in the tuberomamillary nucleus project to
nearly all regions of the brain. Emphasized here are the histaminergic projections to basal ganglia, in particular the striatum (blue), and the input structures to the basal ganglia,
namely the cortex and thalamus. The histaminergic neurons ﬁre at high frequency during wakefulness and are virtually silent during sleep.
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et al., 2005; Yin and Knowlton, 2006). The striatum is the main
input nucleus of the basal ganglia, receiving and integrating cortical
and thalamic excitatory glutamatergic input (Doig et al., 2010;Huerta-Ocampo et al., 2014) and exerts a strong control on down-
stream basal ganglia nuclei and behaviour.
The main neuronal type of the striatum, making up approxi-
mately 95% of all neurons in the striatum, is the GABAergic
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two classes; the dopamine receptor 1 (D1)-expressing and dopa-
mine receptor 2 (D2)-expressing MSNs. The remaining 5% of striatal
neurons are comprised of a variety of cholinergic and GABAergic
interneurons (Kawaguchi et al., 1995;Mallet et al., 2005), which can
locally control the activity of the MSNs. The D1 and D2-expressing
MSNs are the projection neurons of the striatum and give rise to the
so-called direct and indirect pathways, respectively (Gerfen et al.,
1990; Smith et al., 1998) depending on their projections to down-
stream nuclei of the basal ganglia.
The direct pathwayMSNs project directly to the output nuclei of
the basal ganglia; the globus pallidus internus (GPi) and substantia
nigra pars reticulata (SNr). These two nuclei consist of tonically
active GABAergic neurons whose main target are the glutamatergic
neurons of the motor thalamus. The activity of the striatal
GABAergic D1 MSNs will inhibit the activity of the GPi and SNr
neurons and in effect allow a release of their GABAergic control of
thalamic activity, which is then able to activate the motor cortex
neurons and facilitate movement. Conversely the indirect MSNs
project to the GPi and SNr indirectly as they make their synapses
ﬁrst with the GABAergic neurons of the globus pallidus externus
(GPe). GPe projects to the subthalamic nucleus, which then projects
to GPi and SNr as well as sending projections directly to the SNr and
GPi. In effect the activity of striatal GABAergic D2 MSNs will inhibit
the tonically active neurons of the GPe. The reduced activity of the
GABAergic neurons of the GPe will allow for an increased activity of
GPi and SNr neurons and a stronger inhibitory control of thalamic
neurons (Fig. 1A). Although this is an oversimpliﬁcation, it is
thought that through balanced activity in these two pathways; the
direct D1 pathway facilitating movement and the indirect D2
pathway inhibiting movement the striatum can exert control on
motor behaviour (Kravitz et al., 2010; Gerfen and Surmeier, 2011).
The activity of the MSNs is not only determined by excitatory
glutamatergic input but further controlled by local GABAergic and
cholinergic interneurons which make up the remaining 5% of
striatal neurons (Kawaguchi et al., 1995; Mallet et al., 2005). MSNs
also regulate each other through reciprocal inhibitory connections
(Plenz, 2003). Lastly, a large number of neuromodulators including
histamine (Haas and Panula, 2003; Ellender et al., 2011) and
dopamine (Schulz, 2002; Ungless, 2004; Surmeier et al., 2007),
among others (Aston-Jones and Bloom, 1981; Steinbusch, 1981;
Mathur et al., 2011; Parent et al., 2011), can control the activity of
this circuit in complicated ways. The combined excitatory drive to
the MSNs and the neuromodulatory state of the striatum will
determine if and when the MSNs ﬁre action potentials and the
balance in activity between these two pathways will differentially
affect motor behaviour (Kravitz et al., 2010).
To understand how neuromodulators can control the activity of
complex circuits such as the basal ganglia we need to understand
when, where and how they exert their effect. We need to know
when histamine is released, where histamine can act, i.e. which
brain regions and neurons express histamine receptors, and how
this affects the electrical properties of the neurons and by extension
the circuit they comprise. There is now strong evidence that his-
tamine exerts control on the activity of the striatum and as such the
behaviour of the basal ganglia as a whole, which we will discuss in
the next section.
3. Histamine and the striatum
3.1. Diurnal release of histamine in the striatum
The histaminergic neurons in the TMN of the hypothalamus ﬁre
at high frequency during wakefulness (Takahashi et al., 2006; Saper
et al., 2010; Lin et al., 2011) and are virtually silent during sleep(Haas and Panula, 2003; Takahashi et al., 2006, 2010; Sakai et al.,
2010). The histaminergic neurons project to nearly all parts of the
brain (Watanabe et al., 1983; Haas and Panula, 2003) including a
projection to the striatum (Fig. 1B). The release of histamine occurs
at both the dendritic and axonal arbour through synaptic and non-
synaptic release mechanisms (Cumming et al., 1991) and exhibits a
diurnal release in many brain structures (Mochizuki et al., 1992;
Chu et al., 2004; Zant et al., 2012) most likely including the stria-
tum (Cumming et al., 1991; Adachi et al., 1992; Yoshitake et al.,
2003; Castellan Baldan et al., 2014), although complete 24-h
microdialysis experiments have yet to be explicitly done for this
structure. Thus, it is likely that histamine can exert a diurnal control
on the activity of the basal ganglia circuitry. Not only does the ac-
tivity of histaminergic neurons follow a circadian rhythm it has
recently been shown that the mRNA levels of the histamine syn-
thesizing enzyme histidine decarboxylase (HDC) also exhibit a
diurnal rhythm (Yu et al., 2014) emphasizing a tight diurnal synergy
between neural activity and gene expression in this structure.
Nevertheless, histaminergic neurons can become active and release
histamine immediately and independent of the time of waking
(Zant et al., 2012), which suggests that the amount of histamine
synthesized and released might well be different when wakeful-
ness occurs outside of the normal circadian rhythm (Yu et al., 2014).
Within periods of wakefulness histaminergic neurons further
regulate their activity, such that they are highly active during pe-
riods of increased attention (Takahashi et al., 2006) and certain
motivated behaviours (Torrealba et al., 2012). Although the hista-
minergic neurons of the TMN are the only neurons producing
histamine in the adult brain, other neurons have been shown to
express the synthesizing enzyme HDC (Zecharia et al., 2012) or
histamine (Vanhala et al., 1994) transiently early in development.
Indeed mast cells might also be a further source of striatal hista-
mine (Russell et al., 1990; Watanabe and Wada, 1991).
To date no speciﬁc histamine transporters or uptake mecha-
nisms have been described in the brain, although low afﬁnity
organic cation transporters might play a role in the uptake of his-
tamine (Amphoux et al., 2006). Thus, histamine is considered to be
inactivated in the extracellular space by histamine methyltransferase
(HMT) with a half-life ranging in the tens of minutes (Pollard et al.,
1974; Cumming et al., 1991; Schwartz et al., 1991). This suggests
that histamine released by tonically active histaminergic neurons
during periods of wakefulness (Reiner and McGeer, 1987;
Steininger et al., 1999; Takahashi et al., 2006) may diffuse from
the site of release and affect large, if not all, areas of the striatum.
Although shown immunohistochemically (Vincent et al., 1983) a
recent study demonstrated that a subset of TMN neurons can also
co-release the neurotransmitter GABA which can act in a compa-
rable paracrine fashion (Yu et al., 2015), affecting both the electrical
properties of striatal neurons and motor behaviour, suggesting that
both may act in concert across large areas of the striatum.
3.2. Striatal expression of histamine receptors
The high expression of histamine receptors in the striatum (Hill
and Young, 1980; Martinez-Mir et al., 1990; Vizuete et al., 1997;
Pillot et al., 2002) supports the notion of a widespread effect of
histamine on striatal function. To date three main types of hista-
mine receptors (H1, H2 and H3 receptors), all G-protein coupled
receptors (GPCRs), have been described in the striatum, which can
respond to the released histamine (Haas and Panula, 2003). The H1
receptor (Hill and Young, 1980; Yamashita et al., 1991) and H2 re-
ceptor (Gantz et al., 1991; Traiffort et al., 1992) are mainly post-
synaptic receptors positively coupled to intracellular pathways
controlling excitability and indeed their activation has mostly
excitatory actions on neurons (Schwartz et al., 1991; Haas and
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aptic receptor regulating neurotransmitter release through the
negative modulation of Ca2þ inﬂow through voltage-activated Ca2þ
channels (Brown and Haas, 1999), but postsynaptic effects cannot
be excluded (Ellenbroek and Ghiabi, 2014). The H3 receptor
(Lovenberg et al., 1999) is especially highly expressed in the stria-
tum as shown in a series of studies (Pollard et al., 1993; Cumming
and Gjedde, 1994; Goodchild et al., 1999; Pillot et al., 2002;
Gonzalez-Sepúlveda et al., 2013). Lastly, the recently described H4
receptor seems to be highly expressed by cells of hematopoietic
origin and preliminary evidence suggests it might be expressed in
the CNS also (Connelly et al., 2009; Strakhova et al., 2009), but this
needs further study. Several excellent recent reviews on hista-
minergic receptors can be found in this special issue and elsewhere
(Leurs et al., 2009; Panula et al., 2015).
3.3. Functional evidence of histaminergic modulation of striatal
circuits
One of the ﬁrst suggestions that histamine might affect the
circuits of the basal ganglia was detailed in a publication in the
journal Neuropharmacology nearly 40 years ago (Nowak et al.,
1977). In this study the authors observed that injection of hista-
mine in the lateral ventricles of rats induced hypokinesia or aki-
nesia, which was discussed in the context of histaminergic
modulation of the cholinergic system of the basal ganglia. A similar
decrease inmotor behaviour, but followed by a transient increase in
locomotion, was later seen after direct injections of histamine in
the striatum (Bristow and Bennett, 1988). Already shown for other
brain regions (Haas and Konnerth, 1983; McCormick and
Williamson, 1991), the earliest functional evidence that histamine
directly affected striatal neurons consists of the observation that
histamine canmodulate the intrinsic electrical properties of striatal
cholinergic interneurons (Munakata and Akaike, 1994). In this
study the authors performed perforated patch-clamp electrophys-
iological recordings from dissociated rat striatal cholinergic in-
terneurons and found that a range of concentrations of histamine
can depolarize cholinergic neurons by acting at H1 and H2 receptors
and reducing an outward Kþ current. This depolarizing effect was
later conﬁrmed by subsequent in vitro studies in acute striatal slices
(Bell et al., 2000) and in vivo studies showing an increase in
acetylcholine release upon microdialysis of histamine (Prast et al.,
1999a, b), although the latter authors suggest there might be an
indirect way to activate cholinergic interneurons through actions of
histamine at dopaminergic afferents. That histamine can also have
inhibitory effects on striatal circuits was shown in subsequent
studies. For example, it was shown that histamine can negatively
regulate the release of GABA from MSNs by acting at H3 receptors
(Garcia et al., 1997) in acute SNr slices containing the MSN stria-
tonigral terminals, as well as in acute striatal slices (Arias-Montano
et al., 2001). Subsequent studies showed that histamine could also
reduce the release of glutamate from striatal synaptosomes
(Molina-Hernandez et al., 2001), as well as reduce the electrically
evoked glutamatergic ﬁeld responses in corticostriatal slices
(Doreulee et al., 2001; Sergeeva et al., 2005), both by acting at H3
receptors.
It was thus clear that histamine could regulate some aspects of
the striatal circuit but there were still many questions outstanding.
These included the potential modulation of the thalamic projection
to the striatum, which forms the other major excitatory gluta-
matergic afferent to the striatum (Smith et al., 2014), and the po-
tential differential modulation of the two main types of striatal
MSN (see Table 1) Indeed, several in vivo studies of the activity
patterns in the striatum came to different conclusions on the effect
of histamine on striatal neural activity with both increases (Sittigand Davidowa, 2001) and decreases (Chronister et al., 1982) in
neural activity reported upon histamine infusion in vivo. Most likely
these conﬂicting results result from the inherent heterogeneity of
striatal neurons. The aim of our recent study was therefore to
investigate the histaminergic modulation of the striatum using an
in vitro slice preparation where we could control for this hetero-
geneity using post hoc morphological and immunohistochemical
identiﬁcation of recorded cells (Ellender et al., 2011) as well as
including all main striatal glutamatergic and GABAergic afferents.
Future studies of the effect of histamine on the striatal circuit ac-
tivity in vivowill likely beneﬁt from similar techniques allowing for
post hoc anatomical classiﬁcation of neuron type (Huerta-Ocampo
et al., 2014).
In our study we investigated the effect of 10 mM histamine
application on striatal synaptic transmission in acute brain slices of
adult mice. Although this concentration is effective to study his-
tamine in vitro (Brown and Haas, 1999; Atzori et al., 2000; Doreulee
et al., 2001) it must be kept in mind that histamine concentrations
in the intact brain might well be lower (Yoshitake, 2003; Chu et al.,
2004). Deciding on the correct concentration is a general problem
with in vitro preparations, as it is difﬁcult to predict what the ﬁnal
concentration within the tissue will be. Moreover, acute striatal
slices were generated in the morning of each day, corresponding to
the dormant stage for mice, which could well affect the neuronal
responses to histamine application as histamine receptor mem-
brane expression might also be under diurnal regulation analogous
to other receptors (Karatsoreos et al., 2006).
We ﬁrst investigated the effect of histamine on corticostriatal
transmission and the membrane voltage of recorded MSNs. Viral
delivery of the light-activatable channel channelrhodopsin-2
(ChR2) (Zhang et al., 2006) in the cortex of CAMKII-cre mice
allowed for the expression and subsequent light activation of
cortical excitatory neurons. We ﬁnd that both electrical stimulation
of the cortical ﬁbres in the external capsule or optogenetic activa-
tion of cortical ﬁbres could elicit glutamatergic EPSPs in recorded
MSNs which were reduced in amplitude by histamine to a similar
degree (by approximately 20e40%) for both D1 and D2-expressing
MSNs. Co-application of histamine and the H3 receptor antagonist
thioperamide abolished this effect suggesting that histamine acts at
the H3 receptors to negatively modulate cortical glutamatergic
transmission, consistent with previous observations (Doreulee
et al., 2001). Both types of MSN signiﬁcantly depolarized in the
presence of histamine, by approximately 7 mV, through activation
of H2 receptors as this effect could be blocked by the antagonist
ranitidine.
Next, we investigated the effect of histamine on the second
major excitatory glutamatergic afferent pathway to striatal MSNs
coming from the thalamus and speciﬁcally the intralaminar
thalamic nuclei (Groenewegen and Berendse, 1994; Lacey et al.,
2007; Ellender et al., 2013; Smith et al., 2014). We used an opto-
genetic approach to improve the isolation of thalamic afferents to
the striatum and avoid erroneous activation of passing ﬁbres or
disynaptic activation (thalamo-cortico-striatal), which could result
from using conventional electrical stimulation. We found that
histamine reduces the thalamic excitatory input to both D1 and D2-
expressing MSNs (by approximately 60%) and this also depended
on the H3 receptor. This is the ﬁrst observation that histamine
strongly controls the glutamatergic release from thalamic ﬁbres in
the striatum. Moreover, a direct histaminergic modulation of the
thalamus itself is also likely as the thalamus exhibits high levels of
H3 receptors (Pollard et al., 1993). Indeed it has been shown that the
activity pattern of thalamic neurons can be modulated by infusion
of histamine in vivo altering their pattern of ﬁring (Sittig and
Davidowa, 2001). The fact that the histaminergic system, impor-
tant for the maintenance of arousal and vigilance (Lin et al., 1988;
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thalamic nuclei and thalamostriatal synapses ﬁts with the idea that
the intralaminar nuclei have a general activating role in multiple
brain regions (Groenewegen and Berendse, 1994; Kinomura et al.,
1996; Matsumoto et al., 2001).
To investigate if the observed histaminergic modulation of
synaptic transmission occurred presynaptically on cortical and
thalamic afferents we performed paired-pulse stimulation experi-
ments. These consisted of two sequential stimulations, given either
electrically or optically in close succession, which can reveal if
synapses exhibit short-term facilitation (postsynaptic responses
which sequentially increase in amplitude) or short-term depres-
sion (postsynaptic responses which sequentially decrease in
amplitude) of their baseline responses (Thomson, 2000). They can
reveal if neuromodulators such as histamine act presynaptically as
this would likely affect the paired-pulse ratio at these synapses. We
found that histamine signiﬁcantly modulates the paired-pulse ratio
at both cortical (see also Gonzalez-Sepúlveda et al., 2013 and
Doreulee et al., 2001) and thalamic afferents on both types of MSN,
which could be blocked by application of the H3 receptor antagonist
thioperamide. Histamine altered the paired-pulse ratio at thalamic
synapses to such an extent that they converted from depressing to
facilitating synapses. This suggests that thalamic inputs are selec-
tively facilitated over cortical inputs during periods of histaminer-
gic innervation i.e. during wakefulness. It is important to realize
that the use of optogenetic tools are not without confounds. As
ChR2 is calcium permeable this could alter the short-term plastic
properties of synapses. Indeed, it was recently shown that the
short-term plastic properties of a host of synapses differed whether
electrical or optogenetic stimulation was used and even differed
depending on the serotype of adeno-associated virus (AAV) used
for ChR2 plasmid delivery (Jackman et al., 2014). Although thala-
mostriatal synapses were not included in this study it would sug-
gest that the modulatory role of histamine on thalamostriatal
synapses should be revisited using different methodologies, e.g.
using conventional electrical stimulation in brain slices cut at a
particular angle to retain the thalamostriatal afferents (Smeal et al.,
2007, 2008; Ding et al., 2008).
Next, we investigated to what extent striatal GABAergic trans-
mission was modulated by histamine. As a ﬁrst approach we
investigated bulk GABAergic transmission in the striatum by
placing an electrical stimulating electrode in the striatum to acti-
vate all GABAergic afferents simultaneously; likely originating from
local MSNs (Plenz, 2003) and interneurons (Kawaguchi et al., 1995;
Mallet et al., 2005) as well as from extrastriatal locations such as the
GP (Mallet et al., 2012). We found that bulk GABAergic transmission
is signiﬁcantly reduced in the presence of histamine (by approxi-
mately 50%). This mainly seems to be the result of H3 receptor
activation, consistent with previous observations (Arias-Montano
et al., 2001), although for the direct pathway D1-expressing MSNs
part of this negative modulation seems to be the result of histamine
acting at H2 receptors. This latter result could be explained by
histamine acting at the cholinergic interneurons of the striatum
(Munakata and Akaike, 1994; Bell et al., 2000) with the released
acetylcholine acting at the GABergic synapses on D1-expressing
MSNs (Sugita et al., 1991; Koos and Tepper, 2002), although other
neuromodulatory afferents might well be involved (Prast et al.,
1999a; Threlfell et al., 2012). Indeed, a prominent role for hista-
mine in modulating cholinergic neurons was recently reported for
the basal forebrain (Zant et al., 2012) and suggested in mouse
models of L-DOPA induced dyskinesia (Lim et al., 2015). We did not
investigate if histamine co-applied with both H2 and H3 antagonists
simultaneously fully abolished the histamine-induced reduction in
GABA release, which leaves open the possibility for a role for the H1
receptor in modulating striatal GABAergic transmission.Lastly, to isolate speciﬁc types of GABAergic synapses we per-
formed simultaneous patch-clamp recordings from pairs of striatal
neurons. We performed paired recordings from parvalbumin-
positive fast-spiking interneurons and MSNs (Kawaguchi et al.,
1995). Parvalbumin-positive fast-spiking interneurons generate
feedforward GABAergic inhibition of MSNs (Mallet et al., 2005) and
due to the location of their synapses close to the soma of MSNs are
ideally placed to shape MSN spike timing (Koos and Tepper, 1999).
We also performed recordings from pairs of MSNs to investigate the
reciprocal connections between MSNs in the striatum. Reciprocal
connections between MSNs mediate lateral feedback inhibition,
which can either be feedback-facilitatory or feedback-inhibitory
(Plenz, 2003). Due to the location of their synapses across the
extent of theMSN dendritic arbour they are ideally suited to control
the integration of cortical and thalamic excitatory inputs on the
MSNs (Plenz, 2003). We found that histamine only negatively
modulates the reciprocal connections between MSNs and not the
connections between fast-spiking interneurons onto MSNs. It is
likely this is mediated through H3 receptor activation, as shown for
bulk GABAergic transmission, but we did not investigate this
explicitly.
In conclusion, we suggest that histamine dynamically modu-
lates many aspects of the functional connectivity within the stria-
tum. Firstly, histamine suppresses both the cortical and thalamic
excitatory drive to MSNs by acting at presynaptic H3 receptors.
Secondly, histamine selectively modulates the dynamics of thala-
mostriatal, but not corticostriatal, synapses leading to a facilitation
of thalamic input. Thirdly, histamine suppresses lateral feedback
inhibition between MSNs without affecting feedforward inhibition
mediated by parvalbumin-positive fast-spiking interneurons onto
MSNs. These ﬁndings suggest that when histaminergic neurons are
active, such as during wakefulness and periods of increased
attention, the striatum will have a facilitated response to thala-
mostriatal input and be dominated by feedforward inhibition.
Although shown to exist anatomically the lateral inhibitory con-
nections between MSNs were initially thought to be weak or non-
functional (Jaeger et al., 1994). More recently they have not only
been shown to be functional but also rather abundant with con-
nectivity measures ranging from 10% (e.g. 1 functional connection
in 10 putative connections as tested in 5 pairs of MSNs) (Tunstall
et al., 2002), 15% (Planert et al., 2010) to 30% (Taverna et al.,
2008), or even as high as 63% (Chuhma et al., 2011) connectivity.
These recent observations suggest that GABAergic synaptic con-
nections between MSNs are exceedingly well placed to shape
normal striatal activity (Plenz, 2003), and by extent control motor
system output and behaviour (Mink, 1996; Redgrave et al., 1999).
Indeed, striatal disinhibition has been shown to generatemotor tics
in rodents (Bronfeld et al., 2013) and monkeys (McCairn et al.,
2009), which would be consistent with this hypothesis. Our
recent study would suggest that histamine could tightly regulate
this network of lateral inhibitory connections.
What is still largely unknown, and is essential for a complete
understanding of the role of histamine on striatal function is, ﬁrstly,
the modulation of other types of striatal interneurons by histamine
(Kawaguchi et al., 1995; Sharott et al., 2012). Secondly, the direct
modulation of activity in the afferent structures themselves i.e.
cortex (Zant et al., 2012) and thalamus (Groenewegen and
Berendse, 1994; Lacey et al., 2007; Ellender et al., 2013; Smith
et al., 2014; Varela, 2014), although recent investigations are
beginning to address this (Yu et al., 2015). Thirdly, the histamin-
ergic modulation of other striatal neuromodulatory pathways, such
as the noradrenergic (Schlicker et al., 1992) and serotoninergic
pathways (Dere et al., 2004; Threlfell et al., 2004), which would
allow for complex interactions amongst neuromodulators (Threlfell
and Cragg, 2011) as suggested for the dopaminergic pathway (see
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other basal ganglia structures and downstream motor regions
(Chen et al., 2003, 2005) although their widespread projections
(Watanabe et al., 1983; Panula et al., 1984) would suggest so.
Although it is possible to dissect the differential effects of histamine
on all these individual structures and pathways in isolation a
powerful approach to investigate histaminergic control of basal
ganglia behaviour would combine behavioural analysis and the
recording of anatomically identiﬁed neurons (Lapray et al., 2012) in
conjunction with optogenetic technologies to stimulate histamin-
ergic afferents (Yu et al., 2015). This has become technically feasible
with the recent advent of suitable HDC-cre (Yanovsky et al., 2012;
Zecharia et al., 2012) and optogenetic mouse lines (Madisen et al.,
2012). Nonetheless, it is already apparent from current in vivo
studies characterizing the detailed behaviour of histamine-
deﬁcient HDC knockout animals that they exhibit symptoms sug-
gesting basal ganglia dysfunction (Castellan Baldan et al., 2014) as
well as problems regarding wakefulness (Lin et al., 1988;
Parmentier et al., 2002; Anaclet et al., 2009). Indeed, a recently
described patient cohort exhibited both reduced histamine syn-
thesis and aberrant motor behaviour (Ercan-Sencicek et al., 2010),
suggesting a central role for histamine in controlling normal basal
ganglia function and an aberrant histaminergic system in basal
ganglia disorders.
4. Histamine and striatal disorders
The striatum is the site of several devastating neurological dis-
orders and altered striatal function has been implicated in Parkin-
son's disease and Huntington's disease, which we will discuss
below in the context of the histaminergic system, as well as
schizophrenia and addiction amongst others (Simpson et al. 2010;
Graybiel, 2000; Kreitzer and Malenka, 2008; Robbins et al., 2008).
4.1. Parkinson's disease
Several studies have used post-mortem brain tissue of Parkin-
son's disease patients to investigate potential alterations in the
histaminergic system and the basal ganglia. The number of hista-
minergic neurons of the TMN (Nakamura et al., 1996) and HDC
activity (Garbarg et al., 1983) appear unaltered in Parkinson's dis-
ease. However, levels of histamine are markedly increased in the
striatum, SNr and GP of Parkinson's disease patients (Rinne et al.,
2002). A similar increase in the levels of histamine, concomitant
with an increase in H3 receptor mRNA expression and H3 receptor
radioligand binding, was shown for a second independent group of
Parkinson's disease patients (Anichtchik et al., 2001), as well as in
the 6-hydroxydopamine (6-OHDA) model of Parkinson's disease in
rats (Ryu et al., 1994; Anichtchik et al., 2000). However, other
studies have found little to no change in H3 receptor expression or
radioligand binding in human Parkinson's disease patients
(Goodchild et al., 1999; Shan et al., 2012) suggesting further
investigation is needed. Indeed, Goodchild et al. found a signiﬁcant
reduction in H3 receptor radioligand binding in tissue of Hunting-
ton's disease, but not Parkinson's disease, patients. Some of these
discrepancies could result from the different methodologies
employed, for example RT-PCR (Shan et al., 2012) and radioligand
binding (Goodchild et al., 1999). Lastly, although the levels of his-
tamine were shown to be increased (Anichtchik et al., 2001; Rinne
et al., 2002) the levels of transcripts for the metabolizing enzyme
HMT have also been shown to be increased (Shan et al., 2012)
suggesting compensatory mechanisms might be in place.
Some of the ﬁndings might result from speciﬁc treatment pro-
grams for the various Parkinson's disease patient groups, such as
treatment with dopaminergic precursors such as L-DOPA. A closelink between the histaminergic and dopaminergic system is likely
as histaminergic neurons in the TMN also express the dopamine-
synthesizing enzyme DOPA decarboxylase (DDC). This, in combi-
nation with their expression of vesicular monoamine transporter
type 2 (VMAT2), which allows them to take-up L-DOPA, suggest
that they might co-release dopamine and histamine in certain
circumstances, such as when Parkinson's patients are treated with
L-DOPA (Yanovsky et al., 2011). Histamine has been shown to
negatively regulate the release of dopamine in the striatum
(Schlicker et al., 1993; Nowak et al., 2008; Castellan Baldan et al.,
2014) consistent with the observation of an increased dopami-
nergic tone in HDC-KO mice (Rapanelli et al., 2014). Lastly, a direct
interaction between histaminergic H3 receptors and dopamine re-
ceptors has been shown to occur in co-expressing culture systems
(Ferrada et al., 2009) and potentially to occur also in vivo (Moreno
et al., 2011). Together these lines of evidence suggest a potential
synergy between the histaminergic and dopaminergic systems in
Parkinson's disease which warrants further investigation (Table 1).
4.2. Tourette's syndrome
Recent evidence has implicated a speciﬁc dysfunction of the
histaminergic system in the symptoms of Tourette's syndrome
(Ercan-Sencicek et al., 2010). Tourette's syndrome involves un-
controllable motor and vocal tics in which the dysfunction of the
cortico-striato-thalamo-cortical recurrent pathway is thought to
play a major role (Jeffries et al., 2002). We will discuss this ﬁnding
in the context of our recent observations of histaminergic control of
basal ganglia circuits and the idea that reduced levels of histamine
might facilitate crosstalk between the normally segregated path-
ways of the cortico-striato-thalamo-cortico loop.
The study of Ercan-Sencicek and colleagues describes a linkage
study of a family in which all children developed Tourette's syn-
drome. Through linkage analysis the authors ﬁnd a mutation on
chromosome 15 in the gene encoding for the histamine-
synthesizing enzyme HDC in the father only. This mutation con-
sisted of a G to A base mutation leading to a W317X, tryptophan to
missense, transition in exon 9 of the HDC gene resulting in a pre-
mature stop codon resulting in a truncation of the HDC protein. This
truncated protein (a 35 kD instead of the normal 54 kD protein)
misses key segments of the active domain and acts as a dominant
negative mutation as it negatively affects the enzymatic activity of
any remaining healthy copies. It is thought to be a rare mutation, as
it was not found in the wider population or indeed in a second
independent large cohort of Tourette's syndrome patients. None-
theless, it points to a clear role for histaminergic transmission in the
mechanism and modulation of Tourette's syndrome and tics.
Indeed, similar discoveries of rare genetic disorders in Parkinson's
disease such as mutations in the ɑ-synuclein gene (Mezey et al.,
1998) and in Alzheimer's disease in the amyloid precursor protein
gene (Chartier-Harlin et al., 1991; Goate et al., 1991; Murrell et al.,
1991) have enabled studies leading to detailed insight in disease
aetiology.
To gain mechanistic insight a recent comparative study of HDC
gene function was performed in wildtype, heterozygous (HET) and
KO animals for the HDC gene (Castellan Baldan et al., 2014). In this
study the authors conﬁrmed that in HDC transgenic mice, as sug-
gested for Tourette's syndrome patients, brain histamine concen-
trations were signiﬁcantly reduced. The mice had a gene-dose
dependent decrease in histamine concentration in the hypothala-
mus, striatum and cortex in both the HET and KO mice suggesting
haploinsufﬁciency. Although the general baseline behaviour of the
transgenic mice appeared normal they exhibited a decrease in pre-
pulse inhibition of startle responses. This was also observed in the
W317X patient cohort and is a hallmark of deﬁcits or abnormalities
Table 1
Histaminergic modulation of striatal afferents and striatal neurons.
Experimental design Effect of histamine Receptors Reference
Glutamate
Cortex Electrical stimulation of cortical afferents and striatal
ﬁeld recordings in vitro
Decrease release H3 Doreulee et al. (2001)
4-AP induced glutamate release from synaptosomes
in vitro
Decrease release H3 Molina-Hernandez et al. (2001)
Electrical stimulation of cortical afferents and striatal
ﬁeld recordings in vitro
Decrease release ? Sergeeva et al. (2005)
Electrical and ChR2-mediated optical stimulation of
cortical afferents in striatal slices
Decrease release H3 Ellender et al. (2011)
Electrical stimulation of cortical afferents and striatal
ﬁeld recordings in striatal slices
Decrease release H3 Gonzalez-Sepulveda et al. (2013)
Thalamus 4-AP induced glutamate release from synaptosomes
in vitro
Decrease release H3 Molina-Hernandez et al. (2001)
ChR2-mediated optical activation of thalamic
afferents in striatal slices
Decrease release H3 Ellender et al. (2011)
GABA
MSNs High [Kþ] and D1 agonist induced [3H]GABA release
in SNr slices
Decrease release H3 Garcia et al. (1997)
Paired whole-cell patch-clamp recordings in striatal
slices
Decrease release ? Ellender et al. (2011)
Parvalbumin
interneurons e MSNs
Paired whole-cell patch-clamp recordings in striatal
slices
No change e Ellender et al. (2011)
Other GABAergic sources High [Kþ] and D1 agonist induced [3H]GABA release
in striatal slices
Decrease release H3 Arias-Montana et al. (2001)
Intrastriatal electrical stimulation evoked bulk GABA
release in striatal slices
Decrease release H3 and H2 Ellender et al. (2011)
Cholinergic interneurons
High [Kþ] activation of disscociated Cholinergic
interneurons
Depolarization H1 and H2 Munakata and Akaike (1994)
Histamine induced acetylcholine release in striatum
in vivo
Increase release H3 Prast et al. (1999b)
Whole-cell patch-clamp of ChI in striatal slices Depolarization H1 Bell et al. (2000)
Dopamine
Electrical stimulation of [3H]dopamine release in
striatal slices
Decrease release H3 Schlicker et al. (1993)
Generation of [3H]dopamine in striatal tissue Reduced synthesis H3 Gonzalez-Sepulveda et al. (2013)
4-AP: 4-aminopyridine.
ChR2: channelrhodopsin-2.
SNr: substantia nigra pars reticulata.
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with increased locomotion upon amphetamine administration,
both HET and KO animals responded with an increase in a range of
stereotypies such as repetitive focussed snifﬁng and orofacial
movements reminiscent of the symptoms found in Tourette's syn-
drome patients. This behavioural phenotype could be attenuated by
pre-treatment with the D2 receptor antagonist, haloperidol, or
infusion with histamine. Histamine infusion likely reduces the
concentration of dopamine in the striatum by acting at H3 receptors
on dopaminergic afferents (Schlicker et al., 1993). Indeed, Castellan
Baldan and colleagues ﬁnd that dopamine levels are increased in
HDC KO mice. The chronic increased levels of dopamine could lead
to alterations in the expression of dopamine receptors and indeed
they ﬁnd that the levels of D2/D3 receptor expression in the SNr and
pallidum of W317X patient and KO mice are increased. Although
changes were observed in the striatum they were modest. In
conclusion, these studies suggest that reduced histamine produc-
tion can produce symptoms of Tourette's syndrome potentially
through dysregulation of dopaminergic modulation of the basal
ganglia and further emphasizes a functional association between
the histaminergic and dopaminergic systems (Ferrada et al., 2009;
Moreno et al., 2011; Yanovsky et al., 2011; Rapanelli et al., 2014).
A powerful concept guiding basal ganglia research has been the
idea of parallel cortico-striato-thalamo-cortical loops specialized
for the processing of different types of behaviourally relevant in-
formation (Alexander et al., 1986; Haber and Knutson, 2010; Choi
et al., 2012). It has been suggested that the degree of interactionbetween competing excitatory inputs needs to be tightly regulated
as insufﬁcient inhibition of competing pathways can lead to erro-
neous activation of unwanted actions, seen for example as motor
and verbal tics, such as those seen in Tourette's syndrome.
Conversely, overriding inhibition of competing pathways can
hinder behavioural or attentional switching as seen in addictive
compulsions and obsessive-compulsive disorders (Redgrave et al.,
1999). Such crosstalk could arise within or between any of the
different basal ganglia nuclei including the striatum. In the striatum
the GABAergic MSNs account for the majority of neurons and the
majority of all synaptic connections in the striatum consist of the
lateral GABAergic inhibitory connections between MSNs. Our
recent observation of strong histaminergic control of this network
of lateral feedback inhibitory connections between MSNs (Ellender
et al., 2011) and observations of altered striatal histaminergic tone
in Tourette's syndrome (Castellan Baldan et al., 2014) could suggest
that this might well be the site at which dysfunctional crosstalk
between normally segregated pathways could occur. Indeed, al-
terations in the histaminergic and GABAergic systems (Kalanithi et
al., 2005; Kataoka et al., 2010) are thought to be common features
in tic disorders (Fernandez et al., 2012).
5. Conclusion
These are exciting times for the study of the neuromodulator
histamine and its role in regulating neural circuit activity.
Increasing evidence points to a role for histaminergicmodulation of
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dysfunction is causally related to Tourette's syndrome and hista-
minergic supplementation alleviates part of the symptoms war-
rants investigation whether other tic disorders might also beneﬁt
from histaminergic treatment. Indeed, investigations of the thera-
peutic potential of various drugs acting at histamine receptors
(Huotari et al., 2000; Gomez-Ramirez et al., 2006; Kuhne et al.,
2011; Passani and Blandina, 2011) in either treating neurological
disorders or enhancing treatment efﬁcacy (Johnston et al., 2010) are
ongoing. The development of new transgenic mouse lines, such as
the HDC-cre lines (Yanovsky et al., 2012; Zecharia et al., 2012) and
histamine receptor KO lines (Toyota et al., 2002) will prove
invaluable for future research. Lastly, observations of heterogeneity
of the histaminergic neurons in the TMN (Blandina et al., 2012;
Giannoni et al., 2009; Williams et al., 2014; Yu et al., 2015) in co-
expression of other neurotransmitters, receptor expression and
distinct projection targets, suggests complexity which will need to
be taken into account if we are to understand how histamine
controls various neural circuits and behaviour.
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